Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;45(3):945–962. doi: 10.3892/or.2021.7930

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Szczygieł et al.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 3. — Impact of chemotherapy on infiltration of MC38 tumor nodules with immune cells. (A) Scheme of treatment. (B) Schemes of multiparameter flow cytometry analyses showing the method of distinguishing myeloid or lymphoid cell subpopulation in tumors dissected from MC38 tumor-bearing mice treated according to the scheme presented in A. (C) Percentage of CD45⁺ cells in tumor nodules. (D-G) Percentage of myeloid cell subpopulations among CD45⁺ cells in tumors. (H) M1/M2 ratio showing changes in polarization of tumor-infiltrating macrophages after therapy. (I-K) Percentage of DCs infiltrating into tumor tissue and expression of MHC II and CD80 molecules on the surface of DCs. (L-P) Percentage of lymphoid cell subpopulations among CD45⁺ cells in tumors. Results are expressed as mean ± SD (5 mice per group were analyzed from one experiment). In all presented data the differences between groups were calculated using the one-way ANOVA followed by Tukey's multiple comparison post-hoc test (*P<0.05, **P<0.01). HES, hydroxyethyl starch; MTX, methotrexate; DCs, dendritic cells; TAMs, tumor-associated macrophages; Mf, macrophages; M-MDSC, monocytic myeloid derived suppressor cells; PMN-MDSC, polymorphonuclear myeloid derived suppressor cells; Tregs, regulatory T cells; NK, natural killer; i.v., intravenously s.c., subcutaneously.